[Media Releases] [Etoday] LegoChem and Green Cross signed an agreement for development of anticoagulant

Title: LegoChem and Green Cross signed an agreement for development of anticoagulant 

Publication:  Etoday / Sang Heui Cho

Date: 8 June 2009

Summary 

• Green Cross and LegoChem Biosciences signed an agreement on the development and sales of Fxa inhibitor anticoagulant for an exclusive worldwide market right.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).